NASDAQ: ZVRA
Zevra Therapeutics Inc Stock Ownership - Who owns Zevra Therapeutics?

Insider buying vs selling

Have Zevra Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
John B. BodeDirector2026-03-2439,200$4.97
$194.82kBuy
John B. BodeDirector2026-03-2439,200$4.89
$191.69kBuy
Neil F. McFarlanePresident and CEO2026-02-0914,625$8.56
$125.19kSell
Joshua SchaferCCO2026-02-0310,500$9.19
$96.51kSell
Timothy J. SangiovanniSVP Finance Corp Controller2026-02-033,000$9.18
$27.55kSell
Neil F. McFarlanePresident and CEO2026-02-0291,000$9.38
$853.40kSell
Rahsaan ThompsonChief Legal Compliance2026-01-304,080$8.83
$36.01kSell
Adrian W. QuartelChief Medical Officer2026-01-304,533$8.83
$40.04kSell
Timothy J. SangiovanniSVP Finance Corp Controller2026-01-301,750$8.82
$15.44kSell
Joshua SchaferCCO2026-01-303,375$8.83
$29.80kSell

1 of 2

ZVRA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ZVRA insiders and whales buy or sell their stock.

ZVRA Shareholders

What type of owners hold Zevra Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc7.68%4,507,051$41.28MInstitution
Delaware Street Capital Master Fund LP6.98%4,095,914$37.52MInsider
Woodline Partners LP5.88%3,450,844$31.61MInstitution
Vanguard Group Inc5.63%3,305,207$30.28MInstitution
Samuel J. Braun5.35%3,143,000$28.79MInsider
Christal M. M. Mickle4.58%2,690,545$24.65MInsider
Fmr LLC4.08%2,393,493$21.92MInstitution
Nantahala Capital Management LLC3.02%1,771,936$16.23MInstitution
State Street Corp2.53%1,482,956$13.58MInstitution
Geode Capital Management LLC2.29%1,341,681$12.29MInstitution

1 of 3

ZVRA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ZVRA64.97%21.95%Net SellingNet Selling
VALN2.99%0.00%
CRMD53.08%9.65%Net SellingNet Selling
IVA48.83%0.00%
YDES0.20%3.67%

Zevra Therapeutics Stock Ownership FAQ

Who owns Zevra Therapeutics?

Zevra Therapeutics (NASDAQ: ZVRA) is owned by 64.97% institutional shareholders, 21.95% Zevra Therapeutics insiders, and 13.08% retail investors. Delaware Street Capital Master Fund LP is the largest individual Zevra Therapeutics shareholder, owning 4.10M shares representing 6.98% of the company. Delaware Street Capital Master Fund LP's Zevra Therapeutics shares are currently valued at $37.52M.

If you're new to stock investing, here's how to buy Zevra Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.